Related Experiment Video

Updated: Jul 6, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of

Z Sheng Guo1, Stephen H Thorne, David L Bartlett

  • 1University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. guozs@upmc.edu

Biochimica Et Biophysica Acta
|March 11, 2008
PubMed

Insights

Oncolytic viruses (OVs) are engineered to selectively replicate in cancer cells, inducing cell death and stimulating anti-tumor immunity. Researchers are exploring novel delivery methods using tumor-homing cells for enhanced cancer treatment.

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Significant advancements in oncolytic virus (OV) development leverage cancer biology and virology.
  • OVs are genetically engineered for selective replication in cancer cells, inducing apoptosis and host antitumor immune responses.

Purpose of the Study:

  • To review the current state of oncolytic virus (OV) engineering for targeted cancer therapy.
  • To explore novel strategies for OV delivery, including the use of tumor-homing carrier cells.
  • To identify future research directions for optimizing OV-based cancer treatments.

Main Methods:

  • Genetic engineering of OVs to target specific cancer cell molecules and signaling pathways (e.g., RB/E2F/p16, p53, EGFR, Ras, Wnt).
  • Investigation of various OV platforms including adenovirus, herpes simplex virus, poxvirus, and reovirus.
  • Exploration of tumor-homing cells (stem cells, immune cells, cancer cells) as delivery vehicles for OVs.

Main Results:

  • Engineered OVs demonstrate efficient and selective replication in cancer cells, leading to cell death.
  • Targeted pathways and molecules in cancer cells and the tumor microenvironment are being elucidated.
  • Naturally tumor-homing cells show potential as carriers for OV delivery, with chemokine and cell adhesion molecules mediating their trafficking.

Conclusions:

  • Oncolytic viruses (OVs) represent a promising therapeutic strategy for cancer treatment.
  • Further research into OV targeting, delivery systems, and immune interactions is crucial for clinical success.
  • Harnessing tumor-homing cells offers a novel approach to enhance OV delivery and efficacy in cancer therapy.

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...